LCT Signs MOU with NZeno, Secures Pig Cells for NTCELL Trial
Filed with ASX · · 3 pages · English
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- Secures Funds for 3rd Trial of NTCELL in Parkinson Disease
- Preliminary Final Report and 2021 Financial Statements
- LCT Interim CEO Appointed
- LCT exits peptide projects
- LCT CEO Dr Ken Taylor signals intention to retire
Later from Algorae Pharmaceuticals
- LCT Advises Price Change for Rights Issue
- LCT Receives New Zealand R&D Tax Credit
- LCT- Rights Issue
- Prospectus- Rights Issue
- Extension of Rights Issue
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals